Trials / Completed
CompletedNCT00032799
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 905 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | natalizumab |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2003-09-01
- Completion
- 2003-09-01
- First posted
- 2002-04-04
- Last updated
- 2016-06-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00032799. Inclusion in this directory is not an endorsement.